» Authors » Lucia Martin-Banderas

Lucia Martin-Banderas

Explore the profile of Lucia Martin-Banderas including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 143
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Saraiva S, Martin-Banderas L, Duran-Lobato M
Pharmaceutics . 2023 Apr; 15(4). PMID: 37111563
The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which...
2.
Cabeza L, El-Hammadi M, Ortiz R, Cayero-Otero M, Jimenez-Lopez J, Perazzoli G, et al.
Bioimpacts . 2023 Jan; 12(6):515-531. PMID: 36644541
Paclitaxel (PTX) is a cornerstone in the treatment of breast cancer, the most common type of cancer in women. However, this drug has serious limitations, including lack of tissue-specificity, poor...
3.
McGrail J, Martin-Banderas L, Duran-Lobato M
Cannabis Cannabinoid Res . 2022 May; 7(5):582-590. PMID: 35512732
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory distress syndrome coronavirus 2 (SARS-Cov-2), was identified for the first time in late 2019 in China, resulting in a...
4.
El-Hammadi M, Small-Howard A, Jansen C, Fernandez-Arevalo M, Turner H, Martin-Banderas L
Int J Pharm . 2022 Feb; 616():121524. PMID: 35104595
The objective of these in vitro studies was to investigate the impact of the encapsulation of three cannabis-based terpenes, namely β-myrcene (MC), β-caryophyllene (CPh), and nerolidol (NL), on their potential...
5.
Duran-Lobato M, Alvarez-Fuentes J, Fernandez-Arevalo M, Martin-Banderas L
Sci Rep . 2022 Jan; 12(1):1297. PMID: 35079042
Δ-tetrahydrocannabinol (Δ-THC) is known for its antitumor activity and palliative effects. However, its unfavorable physicochemical and biopharmaceutical properties, including low bioavailability, psychotropic side effects and resistance mechanisms associated to dosing...
6.
Jimenez-Lopez J, El-Hammadi M, Ortiz R, Cayero-Otero M, Cabeza L, Perazzoli G, et al.
Pharmacol Res . 2019 Jan; 141:451-465. PMID: 30634051
Paclitaxel (PTX), a chemotherapy agent widely used to treat lung cancer, is characterised by high toxicity, low bioavailability and the need to use of excipients with serious side effects that...
7.
Cayero-Otero M, Espinosa-Oliva A, Herrera A, Garcia-Dominguez I, Fernandez-Arevalo M, Martin-Banderas L, et al.
Curr Pharm Des . 2018 Apr; 24(14):1589-1616. PMID: 29611482
Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the...
8.
Berrocoso E, Rey-Brea R, Fernandez-Arevalo M, Mico J, Martin-Banderas L
Nanomedicine . 2017 Jul; 13(8):2623-2632. PMID: 28756090
Neuropathic pain, resistant to opiates and other drugs, is a chronic/persistent state with a complex treatment and often poor efficacy. In this scenario, cannabinoids are increasingly regarded as a genuine...
9.
Martin-Banderas L, Munoz-Rubio I, Alvarez-Fuentes J, Duran-Lobato M, Arias J, Holgado M, et al.
Colloids Surf B Biointerfaces . 2014 Sep; 123:114-22. PMID: 25262411
The objective of this work is to develop a nanoplatform that can potentiate the oral administration of Δ9-tetrahidrocannabinol, a highly lipophilic active agent with very promising antiproliferative and antiemetic activities....
10.
Duran-Lobato M, Munoz-Rubio I, Holgado M, Alvarez-Fuentes J, Fernandez-Arevalo M, Martin-Banderas L
J Biomed Nanotechnol . 2014 Apr; 10(6):1068-79. PMID: 24749401
This article aimed to produce, characterize and evaluate different surface-modified naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB13) loaded poly(lactic-co-glycolic acid) nanoparticles in order to improve their oral absorption and in vivo biodistribution. Plain and surface-modified...